AC
AVIR icon

Aldebaran Capital’s Atea Pharmaceuticals AVIR Stock Holding History

Aldebaran Capital’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$484K Sell
89,946
-583
-0.6% -$2.68K 0.37% 32
2025
Q4 		$323K Buy
+90,529
New +$288K 0.29% 32
2025
Q2 		– Sell
-37,500
Closed -$112K – 36
2025
Q1 		$112K Buy
+37,500
New +$117K 0.11% 40

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Aldebaran Capital's AVIR Position: Q1 2026 in Review

Aldebaran Capital reduced its Atea Pharmaceuticals (AVIR) stake by 0.64% in Q1 2026, selling an estimated $2.68K and leaving 89,946 shares worth $484K. The position accounts for 0.37% of the portfolio, ranked #32.

Aldebaran Capital first reported a position in AVIR in Q1 2025 and has held it in 3 quarters since. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Aldebaran Capital held 89,946 shares of Atea Pharmaceuticals worth $484K as of Q1 2026.
  • Aldebaran Capital sold 583 Atea Pharmaceuticals shares in Q1 2026, an estimated $2.68K.
  • Atea Pharmaceuticals made up 0.37% of Aldebaran Capital's portfolio in Q1 2026, its #32 holding.
  • Aldebaran Capital first reported a position in Atea Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Aldebaran Capital's 13F filing for Q1 2026, filed 7 May 2026.